Nifekalant

Nifekalant

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 6-[(2-{(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino}ethyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione
CAS Number	130636-43-0^Y
PubChem CID	4486
ChemSpider	4331
UNII	5VZ7GZM43E
CompTox Dashboard (EPA)	DTXSID7048374
Chemical and physical data
Formula	C19H27N5O5
Molar mass	405.455 g·mol^−1
3D model (JSmol)	Interactive image
SMILES Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O
InChI InChI=1S/C19H27N5O5/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29/h5-8,14,20,25H,3-4,9-13H2,1-2H3 Key:OEBPANQZQGQPHF-UHFFFAOYSA-N
(verify)

Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia.^[1] It has the brand name Shinbit.

References

1. Oyabe A, Sano H (February 2002). "Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug". Nippon Yakurigaku Zasshi. 119 (2): 103–9. doi:10.1254/fpj.119.103. PMID 11862758.